Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up

Corvus Pharmaceuticals, Inc. (CRVS) announced that the FDA granted the Orphan Drug Designation to its lead pipeline candidate, soquelitinib, for the treatment of T cell lymphoma.The FDA generally grants this designation to investigational therapies that address rare medical diseases or conditions affecting fewer than 200,000 people in the United States. The perquisites that come from this designation include assistance in the drug development process, tax credits for clinical costs, exemptions from certain ...